



Attorney Docket No.: 4814.214-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Charlotte Johansen Confirmation No: 5761

Serial No.: 09/815,848 Group Art Unit: 1652

Filed: March 23, 2001 Examiner: R. Prouty

For: Antimicrobia1 Peroxidase Compositions

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement (in duplicate)
2. Form PTO/SB/08A
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to the address indicated above on August 19, 2003.

Lourdes Ayala


(name of person mailing paper)

(signature of person mailing paper)

RECEIVED
AUG 21 2003
PATENT
TECH CENTER 1600/2900



Attorney Docket No.: 4814.214-US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Charlotte Johansen Confirmation No: 5761

Serial No.: 09/815,848 Group Art Unit: 1652

Filed: March 23, 2001 Examiner: R. Prouty

For: Antimicrobia1 Peroxidase Compositions

INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(c)

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is enclosed. It is respectfully requested that these references be considered by the USPTO in its examination of the above-identified application and be made of record therein.

This IDS is being filed **after** the period set forth in 37 CFR 1.97(b), but **before** the mailing date of any of a final action, a notice of allowance, or an action that otherwise closes prosecution.


08/22/2003 HAHRED1 00000134 501701 09815848

01 FC:1806 180.00 DA

Accompanying this information disclosure statement is the fee set forth in 37 C.F.R. § 1.17(p). Please charge the fee, estimated to be \$180.00, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this charge directive is attached.

Respectfully submitted,

Date: August 19, 2003


Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212)840-0097

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.**

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner of Patents, Washington, DC 20231.